Barrett & Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$317K Buy
5,493
+105
+2% +$6.03K 0.09% 121
2026
Q1
$327K Buy
5,388
+604
+13% +$35.2K 0.11% 107
2025
Q4
$258K Sell
4,784
-1,503
-24% -$72.3K 0.09% 131
2025
Q3
$284K Buy
6,287
+8
+0.1% +$374 0.1% 124
2025
Q2
$291K Buy
6,279
+6
+0.1% +$295 0.11% 116
2025
Q1
$383K Sell
6,273
-14
-0.2% -$816 0.16% 93
2024
Q4
$356K Buy
6,287
+6
+0.1% +$335 0.15% 94
2024
Q3
$325K Sell
6,281
-1,112
-15% -$52.2K 0.14% 101
2024
Q2
$307K Sell
7,393
-1,572
-18% -$70.3K 0.14% 104
2024
Q1
$486K Sell
8,965
-2,854
-24% -$145K 0.23% 76
2023
Q4
$606K Sell
11,819
-44
-0.4% -$2.31K 0.33% 60
2023
Q3
$689K Sell
11,863
-121
-1% -$7.41K 0.41% 51
2023
Q2
$766K Sell
11,984
-1,787
-13% -$120K 0.44% 48
2023
Q1
$954K Buy
13,771
+45
+0.3% +$3.17K 0.6% 33
2022
Q4
$988K Hold
13,726
0.65% 35
2022
Q3
$988K Buy
+13,726
New +$996K 0.65% 35

Other funds holding BMY

Barrett & Company's BMY Position: Q2 2026 in Review

Barrett & Company increased its Bristol-Myers Squibb (BMY) stake by 1.9% in Q2 2026, buying an estimated $6.03K and bringing the position to 5,493 shares worth $317K. The position accounts for 0.09% of the portfolio, ranked #121.

Barrett & Company first reported a position in BMY in Q3 2022 and has held it in 16 quarters since. The position peaked at $988K in Q4 2022. 863 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Barrett & Company held 5,493 shares of Bristol-Myers Squibb worth $317K as of Q2 2026.
  • Barrett & Company bought 105 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.03K.
  • Bristol-Myers Squibb made up 0.09% of Barrett & Company's portfolio in Q2 2026, its #121 holding.
  • Barrett & Company first reported a position in Bristol-Myers Squibb in Q3 2022 and has held it in 16 quarters since.
  • Barrett & Company's Bristol-Myers Squibb position peaked at $988K in Q4 2022.
  • 863 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.